BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BC Innovations | Mar 25, 2019
Distillery Therapeutics

CD19 CAR T cells for lupus

DISEASE CATEGORY: Autoimmune disease INDICATION: Lupus Mouse studies suggest CD19-targeted CAR T cells could help treat lupus. In two mouse models of lupus, retro-orbital injection of CD19-targeting CAR T cells decreased the number of CD19-positive...
BC Innovations | Feb 21, 2019
Emerging Company Profile

Refuge: Receptive CAR checkpoints

Refuge Biotechnologies Inc. aims to make CAR T cells more potent by suppressing their checkpoint genes and is using a form of CRISPR that knocks the genes down instead of out to improve safety. CEO...
BioCentury | Dec 1, 2018
Product Development

Cell therapy momentum at ASH

This year’s American Society of Hematology (ASH) meeting will showcase a surge in clinical CAR T cell presentations. But gene therapies are not following the same trajectory, despite both modalities being fresh off their first...
BC Innovations | Nov 30, 2018
Targets & Mechanisms

Souped-up CARs at ASH 2018

Rather than searching for new antigens, makers of the latest generation of CAR therapies are focusing on the CARs themselves by designing more sophisticated methods of targeting multiple antigens, controlling cytotoxicity and enhancing tumor-homing. BioCentury’s...
BC Extra | Nov 10, 2018
Preclinical News

June highlights shorter CAR T culture times at SITC

In a presentation at the Society for Immunotherapy of Cancer (SITC) meeting Friday, CAR T cell pioneer Carl June highlighted preclinical data from University of Pennsylvania suggesting CAR T cell therapies could require as little...
BioCentury | Dec 16, 2017
Product Development

Assessing the BCMA scene

Differences in patient populations and a dearth of clinical outcome data mean it’s too soon to declare bluebird bio Inc.’s anti-BCMA chimeric antigen receptor therapy the leader of the pack of CARs that presented clinical...
BioCentury | Dec 9, 2017
Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
BC Extra | Nov 6, 2017
Preclinical News

Team identifies new target for MM CAR T therapy

In a paper published in Nature Medicine , researchers at Osaka University and colleagues identified activated integrin beta(7) as a new target for a chimeric antigen receptor (CAR) T cell therapy for multiple myeloma, demonstrating that...
BC Innovations | Oct 24, 2017
Distillery Techniques

Drug delivery; drug platforms

TECHNOLOGY: Nanoparticles; cell therapy Nanoparticles loaded with mRNA could be used for ex vivo programming of patient-derived CAR T cells as cancer therapies. The nanoparticles consist of a biodegradable poly(β-amino ester) polymer core loaded with...
Items per page:
1 - 10 of 25